Most of the headlines in oncology this month are American: an FDA approval, an FDA decision date, a conference slot. For a European reader the more useful question is where Europe sits in the same wave. The answer is that regulators, patients and clinical sites in the EU are already part of it. A European Medicines Agency committee has recommended a new first-line breast cancer combination, a Swiss-headquartered device maker has just launched in Germany, and German hospitals have produced fresh real-world data on a blood-cancer drug.1,2,3 The dossier we drew on is thinner on the European regulatory detail than we would like, and we say where below.
The European regulatory signal: Trodelvy plus Keytruda
On 24 July 2026 Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency had adopted a positive opinion on Trodelvy plus Keytruda for PD-(L)1-positive, first-line metastatic triple-negative breast cancer.1 The press release says the ASCENT-04/KEYNOTE-D19 trial showed a “highly statistically significant and clinically meaningful” reduction in the risk of disease progression or death.1 That is Gilead's characterisation, not an independent finding.
Evandro de Azambuja, quoted in the release, said: “People with metastatic triple-negative breast cancer need effective treatment options as early as possible in the course of their disease, particularly when their tumors express PD-L1.”1 The release frames a second first-line approval as establishing Trodelvy as a backbone therapy across PD-L1 status in the European Union.1 A CHMP opinion is a recommendation. It is not the final marketing authorisation, and the dossier does not say when the decision will follow.
Novocure: a Swiss company, a German first
Novocure is based in Baar, Switzerland. On 23 July 2026 it reported second-quarter net revenues of $184 million, up 16% year on year, driven by 18% global growth in active patients.2 It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch and more than 280 active patients on the product as of 30 June 2026.2
Chief executive Frank Leonard said: “This was our strongest quarter to date, with record net revenues and active patients on therapy.”2 For European readers the notable point is that a CE Mark, not an FDA decision, gated this launch, and Germany is where it started.2 Via News's analysis of the narrative data treats Novocure's quarter, together with the McKesson/CD&R acquisition of Option Care Health, as evidence of capital moving into oncology services and commercial delivery rather than only into drug discovery.6 The dossier names Option Care Health as headquartered in Bannockburn, Illinois, but it contains no deal terms, so we cannot size the transaction.6
Real-world evidence from 18 German centres
On 12 October 2026 Kyowa Kirin International plc announced the final results of the German MINT study of mogamulizumab (Poteligeo) in mycosis fungoides and Sézary syndrome. The study covered 109 patients across 18 centres.3 The primary endpoint, median time to next treatment, was 14.9 months. The best overall response rate was 62.4% and median progression-free survival was 20.2 months, with quality of life improved from baseline in routine care.3
Real-world studies like this matter to European payers and clinicians because they test whether trial results hold up in everyday practice. The company describes the results as durable. This is a single-arm routine-care analysis published by the manufacturer, and the figures do not show how the drug compares with alternatives.
The US catalysts European investors are watching
On 9 October 2026 the FDA approved Tecentriq and Tecentriq Hybreza, combined with a fluoropyrimidine and oxaliplatin, for adjuvant stage III dMMR colon cancer, based on the Phase III ATOMIC study. It is Tecentriq's twelfth US indication.7 Next comes Summit Therapeutics' ivonescimab: its Biologics License Application, built on the HARMONi trial, has an FDA goal date of 14 November 2026.8 Moderna and Merck plan to present detailed intismeran results at ESMO on 24 October and to engage regulators on possible filings.9 Nurix, developer of bexobrutideg, reported fiscal third-quarter results on 12 October.10
Talent is moving too. Everest Medicines hired two former Moderna cancer-vaccine and oncology translational leaders on 9 October, Brandon Coder and Lakshmi Srinivasan.11 Via News's reading is that this is a sign of cancer-vaccine expertise spreading to other companies. It is our inference, not something the announcements state.
What the SEC filings show about the price of the biggest catalyst
Summit has no product revenue in the periods we hold: revenue was zero in both fiscal 2023 and fiscal 2024.5 Its spending has risen steeply. Operating cash outflow grew from $76.8 million in FY2023 to $142.1 million in FY2024, nearly double, and to $322.9 million in FY2025, more than double again.5 Net loss was $614.9 million in FY2023, $221.3 million in FY2024 and $1,079.6 million in FY2025.5 That last figure is about two and a half times the $419.4 million of cash Summit reported at the second quarter of 2026.5 Loss per share was -$0.99, -$0.31 and -$1.44 across the three years.5
The verified data do not explain why net losses run so far ahead of cash outflow, for example $1.08 billion against $322.9 million in FY2025, so we do not speculate. Capital expenditure is tiny by comparison: $128,000 in FY2023, $139,000 in FY2024 and $657,000 in FY2025.5 This is a company spending on development, not on building plant.
Cash has moved in large steps. It stood at $104.9 million at the end of FY2024 and rose to $211.5 million by the first quarter of 2025 and $297.9 million by the second. It slipped to $238.6 million in the third quarter, closed FY2025 at $225.3 million and fell to $106.5 million in the first quarter of 2026. It then jumped to $419.4 million in the second quarter of 2026.5 The dossier does not say what produced the rebound. A reader who wants to know how the company funds a possible launch should look to Summit's own filings for that.
Summit is a US-listed company, and nothing in our data shows its weight in any European index. The dossier does say that AstraZeneca, which competes with Eli Lilly and develops durvalumab, Enhertu with Daiichi Sankyo, savolitinib and rilvegostomig, is a FTSE 100 constituent.6 It contains no index weighting, so we cannot tell you how much of a tracker fund that represents.
The AI-discovery argument, and how much weight it can bear
An MIT Technology Review piece quotes Puja Sapra on AI-designed biologics. Puja Sapra's central claim concerns data: “Data is our differentiator. We've built an intentionally diverse portfolio across multiple disease areas and drug types. All of that data empowers us to fine-tune frontier AI models with richer, more representative training sets.”4 The piece describes a “lab of the future” in which, in Puja Sapra's words, “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data.”4
Puja Sapra is also frank about the limits: “One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body.”4 On oversight: “With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients.”4 That last point may interest EU readers, given the bloc's attention to explainability. The dossier does not tie it to any specific regulation, and we will not either.
Treat this material as the company's own aspirations. The piece is undated in our records, and in our measured source-reliability check none of the 11 claims examined from this source held up.4 That does not make the quotes inaccurate as quotes. It means we have no independent confirmation of the claims behind them, and none of it is yet visible in an approval or a financial result.
How reliable are the other sources?
The three press-release documents above come from a feed whose claims held up in 56% of 4,960 checks.1,2,3 A figure that low is a reason to read company-issued numbers as company statements. We have therefore attributed results to the announcing companies, and the Summit financials rest on SEC filings, which is why we lead with them where numbers are involved.
What to watch
- 24 October: Moderna and Merck's detailed intismeran results at ESMO, and any word on filings.9
- 14 November: the FDA goal date for ivonescimab. Summit's accounts show how much of the company's financial fate rides on that decision.5,8
- The EU decision on Trodelvy plus Keytruda after the July CHMP opinion. The dossier gives no date.1
- Optune Pax beyond Germany, from the more than 280 patients reported at 30 June.2
